Need professional-grade analysis? Visit stockanalysis.com
$1.28B
N/A
N/A
N/A
Immatics NV (IMTX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $11.26, up 0.72% from the previous close.
Over the past year, IMTX has traded between a low of $4.24 and a high of $11.87. The stock has gained 141.1% over this period. It is currently 5.1% below its 52-week high.
Immatics NV has a market capitalization of $1.28B.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Side-by-side comparison against top Healthcare peers.